Market revenue in 2023 | USD 18.4 million |
Market revenue in 2030 | USD 56.1 million |
Growth rate | 17.2% (CAGR from 2023 to 2030) |
Largest segment | Cytokines & growth factors |
Fastest growing segment | Cytokines & Growth Factors |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones |
Key market players worldwide | Thermo Fisher Scientific Inc, Danaher Corp, Bio-Techne Corp, Sino Biological, Miltenyi Biotec, Proteintech Group, Prospec, New England Biolabs |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to research-grade proteins market will help companies and investors design strategic landscapes.
Cytokines & growth factors was the largest segment with a revenue share of 22.28% in 2023. Horizon Databook has segmented the Australia research-grade proteins market based on cytokines & growth factors, antibodies, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory protein, hormones covering the revenue growth of each sub-segment from 2018 to 2030.
Research-grade proteins are used in various applications in the field of research proteomics in Australia. Researchers are actively investigating the potential of proteomic data. This trend is further expected to boost product demand in the country.
In March 2023, a joint research venture of scientists from the Australian National University's (ANU) Clear Vision research lab and biotech firm VivaZome Therapeutics secured a government grant of USD 3 million.
The novel research by several Australian companies has amplified the revenue generated by the country in the global market. For instance, in June 2023, the FDA approved the clinical trial for Mabwell's IL-11 antibody therapy for IPF. The ongoing Phase 1 trial assesses the safety of 9MW3811 in healthy adults in Australia.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia research-grade proteins market , including forecasts for subscribers. This country databook contains high-level insights into Australia research-grade proteins market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account